JPWO2022211095A1 - - Google Patents

Info

Publication number
JPWO2022211095A1
JPWO2022211095A1 JP2023511743A JP2023511743A JPWO2022211095A1 JP WO2022211095 A1 JPWO2022211095 A1 JP WO2022211095A1 JP 2023511743 A JP2023511743 A JP 2023511743A JP 2023511743 A JP2023511743 A JP 2023511743A JP WO2022211095 A1 JPWO2022211095 A1 JP WO2022211095A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511743A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022211095A1 publication Critical patent/JPWO2022211095A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023511743A 2021-03-31 2022-03-31 Pending JPWO2022211095A1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021060307 2021-03-31
PCT/JP2022/016874 WO2022211095A1 (ja) 2021-03-31 2022-03-31 Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド

Publications (1)

Publication Number Publication Date
JPWO2022211095A1 true JPWO2022211095A1 (bg) 2022-10-06

Family

ID=83459672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511743A Pending JPWO2022211095A1 (bg) 2021-03-31 2022-03-31

Country Status (2)

Country Link
JP (1) JPWO2022211095A1 (bg)
WO (1) WO2022211095A1 (bg)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024071099A1 (ja) * 2022-09-29 2024-04-04 国立大学法人東京医科歯科大学 ５'－シクロプロピレン修飾を含む核酸分子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
KR20150088305A (ko) * 2012-11-26 2015-07-31 로슈 이노베이션 센터 코펜하겐 에이/에스 Fgfr3 발현의 조절을 위한 조성물 및 방법
CN111868244A (zh) * 2018-03-20 2020-10-30 国立大学法人东京工业大学 降低了毒性的反义寡核苷酸
US20220088057A1 (en) * 2019-01-25 2022-03-24 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
WO2020158910A1 (ja) * 2019-02-01 2020-08-06 国立大学法人大阪大学 ５'位修飾ヌクレオシドおよびそれを用いたヌクレオチド

Also Published As

Publication number Publication date
WO2022211095A1 (ja) 2022-10-06

Similar Documents

Publication Publication Date Title
BR112023005462A2 (bg)
BR112023012656A2 (bg)
BR112021014123A2 (bg)
JPWO2022211095A1 (bg)
BR112022024743A2 (bg)
BR102021018859A2 (bg)
BR112022009896A2 (bg)
BR102021007058A2 (bg)
BR102020022030A2 (bg)
BR112023011738A2 (bg)
BR112023016292A2 (bg)
BR112023004146A2 (bg)
BR112023011539A2 (bg)
BR112023011610A2 (bg)
BR112023008976A2 (bg)
BR112023009656A2 (bg)
BR112023006729A2 (bg)
BR102021020147A2 (bg)
BR102021018926A2 (bg)
BR102021018167A2 (bg)
BR102021017576A2 (bg)
BR102021016837A2 (bg)
BR102021016551A2 (bg)
BR102021016375A2 (bg)
BR102021016200A2 (bg)